• Canada-based Ucore Rare Metals Inc. is preparing to begin construction on a rare earth element (“REE”) processing plant in Louisiana that it says will be the first REE separation facility to operate at commercial scale in North America
• Currently, China dominates both REE feedstock supply and REE processing capacity on a global basis, generating concerns that it can control the world’s ability to build modern technologies and use its control to retaliate against countries in adversarial situations
• Modern technologies that rely on REEs for crucial magnets in their composition include phones, computers, household appliances, electric vehicles, solar panels, and wind turbines
• Ucore plans to provide 2,000 metric tons of total rare earth oxides (“TREOs”) annually by late next year, increasing that amount to 5,000 metric tons in 2026

Critical metals production innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is accelerating its efforts to establish a North American-focused supply chain for rare earth elements (“REEs”) since announcing in April that it had reached an agreement to lease an 80,800 square-foot brownfield facility in Alexandria, Louisiana for its first Strategic Metals Complex (“SMC”) facility for REE separation and oxide production.

The company has strengthened its financial position and is working to fulfill plans to launch construction of the Louisiana SMC this year, building to a production capacity of 2,000 metric tons of total rare earth oxides in 2024 and increasing it to 5,000 metric tons in 2026.

Rare earths are vital to many computerized application processes and, though plentiful around the world, tend to make up a small portion of the ores they are found in, requiring a labor-intensive methodology for extracting the REEs.

“It is critical that the United States leads in establishing the critical metals supply chain essential to a changing manufacturing landscape across North America,” Ucore Chairman and CEO Pat Ryan stated in an April 6 company news release (https://ibn.fm/JziR4). “The establishment of the Louisiana SMC in Alexandria represents one of these first building blocks and a significant contributor to the shift toward energy production and consumption diversification.”

China’s dominance of the REE production industries has created concerns in other nations about a potential monopoly on the market by the Asian behemoth. Two years ago, the country consolidated three of its dominant “Big 6” rare earth state-owned enterprises (“SOEs”) into one mega-conglomerate, which now controls up to a quarter of global mineral-bearing REEs and nearly two-thirds of the heavy rare-earth supplies within the country (https://ibn.fm/YQ3Rl). And China also operates roughly 60 percent of world REE production (https://ibn.fm/nq94g), allowing it to weaponize its resources when it wishes to maintain control in international conflicts.

“These minerals power phones and computers, household appliances, electric vehicles and batteries, solar panels, wind turbines, and so much more,” President Biden stated in February (https://ibn.fm/w8iNY). “When it comes to clean energy, China has spent years cornering the market on many of the materials that power the technologies that we rely on. … We can’t build a future that’s made in America if we ourselves are dependent on China for the materials that power the products of today and tomorrow.  And this is not anti-China or anti anything else; it’s pro-American.”

Ucore’s Louisiana facility is expected to use the company’s 100 percent-owned Rapid SX (TM) technology, which has already been successfully piloted in Canada, to operate North America’s first rare earths separation facilities at scale.

“Absolutely we’re behind,” Special Presidential Coordinator Amos Hochstein said in a CNBC interview (https://ibn.fm/J1zOE). “We have to recognize that we have not invested, and that’s what the United States is trying to do now. … We have to learn from what we went through in the oil and gas energy space, as we transition to a new energy market that relies still on natural resources.”

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

Clinical research, contract specialists, clinical operations, regulatory affairs, and legal strategists will all convene at Dynamic Global Events’ (“DGE’s”) 4th Clinical Trial Agreements Forum, returning to in-person learning on August 29-30 in Philadelphia, PA. As the only industry forum to specifically focus on Clinical Trial Agreements (‘‘CTAs’’), this will be a must-attend for legal, regulatory, and clinical contracting professionals who want to stay ahead of the curve on the latest strategies to overcome the industry’s most pressing challenges.

The two-day conference is designed to provide a unique networking and learning experience on the key insights and the latest trends, best practices, and most critical factors impacting the effectiveness and efficiency of your Clinical Trial Agreements. Attendees will enrich their knowledge of how best to structure CTAs that safeguard clinical data in today’s constantly evolving ecosystem—and walk away armed with actionable strategies to expedite timelines and achieve contracting success.

Offering both in-person registrations to maximize networking opportunities and possibilities for organizational improvement, and virtual format to attend for those who cannot make it on-site. On-demand access will also be available to watch the recording of the full conference as well.

No other conference goes into as much detail on these timely and crucial topics:

• Explore CTAs in the Context of DCTs and Remote Monitoring
• Key Considerations for CTA Drafting to Avoid Uninsured Losses
• Accelerate Indemnification Clause Negotiations and Timelines
• Protect IP Rights and Prioritize Data Confidentiality
• Create and Negotiate Master Budgets to Reduce Bottlenecks
• Deep Dive into GDPR: Clarifications and Impact on CTAs
• Structure Patient Injury Language in Subcontracts
• Unravel Difficulties Surrounding Investigator-Initiated CTA clauses
• Effectively Reach Consensus Between Sponsors, Sites, and CROs

Key Takeaways:

DGE’s 4th conference focuses specifically on the most critical challenges surrounding Clinical Trial Agreements and how to overcome them.

• Professional speakers from a wide variety of disciplines and backgrounds—including biopharma, research sites, academia, legal experts, and many more luminaries
• Located in the comfortable and beautiful city of Philadelphia, at the ‘Inn at Penn’, a Hilton Hotel
• Registration is available for in-person or virtual attendance

Behind the scenes:

Dynamic Global Events manages a wide-ranging portfolio of educational gatherings for professionals in the life sciences, utilizing in-person, virtual, and hybrid access capabilities. Its content-driven team provides narrowly focused opportunities for professionals by engaging experts who can address specific challenges and help to develop strategies for creating success.

DGE’s customer-first culture helps life sciences professionals differentiate between content and commercialism while promoting the exchange of critical information between life science professionals and suppliers who support shared goals.

For more information about this event, please visit https://ibn.fm/6ZQEr.

Blockchain technology experts, crypto enthusiasts, investors, and business owners are invited to attend the Web3 Berlin Conference to be held in Berlin, Germany, June 10-11, 2023. As the technological world is on the verge of evolution, the much-awaited Web3 Berlin Conference is set to unveil the potential of associated disruptive technologies.

Hosting the prominent gathering of unique ideas and intellectual minds, Web3 Berlin Conference promises to celebrate technological innovation. The conference has a rich history of successful events, featuring engaging workshops and immersive panel discussions.

The keynote speakers will share insights into blockchain technology, decentralized applications (dApps), decentralized finance (DeFi), and non-fungible tokens (“NFTs”). Attendees will get a unique opportunity to meet visionaries who will share their expertise about decentralized technologies investment opportunities, industry trends, and regulatory challenges.

A Groundbreaking event for Networking and Social Gathering

Web3 Berlin Conference will feature industry pioneers and renowned industry leaders who will share interactive sessions about the latest frameworks, tools, and methodologies for creating decentralized applications. Blockchain developers will get an opportunity to hone their skills and gain valuable insights into real-world projects.

The exhibition area of the conference will feature prominent blockchain companies and startups that will demonstrate the latest industry advancements. By providing ample networking and collaboration opportunities, this dynamic event will enable attendees to launch their innovative projects. Moreover, the Web3 ecosystem will provide them with an opportunity to meet like-minded individuals and crypto investment prospects.

The 2023 Web3 Berlin Conference is designed to nurture an inclusive community, forging new partnerships while driving the global acceptance of Web3 technologies. Interested participants can register now to avail early-bird rates and secure their spot at the epitome of the Web3 revolution.

To learn more, please visit https://ibn.fm/5mTk0.

• Global electrification depends on the availability of graphite to power lithium-ion batteries used in EVs and portable electronic devices
• The Ruby Graphite Deposit is the only combined graphite flake and vein graphite source in the U.S., Reflex secured the option to acquire a 100% stake in the project in 2022
• Reflex engaged Lone Star Tech Minerals to advance Ruby Graphite project, deliverables include a production plan, marketing strategy, customer database, and technical data sheet
• Biden Administration to award $2.8 billion to expand domestic EV battery manufacturing and graphite processing

The worldwide shift to electrification depends on the availability of graphite – a critical element needed to power lithium-ion batteries used in electric vehicles (“EVs”) and portable electronic devices.

The Ruby Graphite Deposit is the only combined graphite flake and vein graphite source in the United States. Acquired last year by Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF), the Ruby Graphite Deposit is a low-cost opportunity to re-enter the market with recent samples assaying at 95.8% to 98.4% total carbon.

RFLXF is aiming to meet surging graphite demands by engaging with Lone Star Tech Minerals (“LSTM”), a Texas-based graphite and industrial minerals marketing consulting firm. Under the partnership, both companies will collaborate to conduct a competitive analysis and develop a market strategy for coated, spherionized, and purified graphite (“CSPG”) (https://ibn.fm/8OxLF).

“We are excited to partner with Lone Star Tech Minerals and leverage their marketing and technical experience,” said Paul Gorman, CEO of Reflex Advanced Materials Corp. “Lone Star’s extensive knowledge of the CSPG industry will be invaluable as we aim to deliver high-quality, custom graphite products to a wide range of industry uses and chemistries to the North American supply chain.”

Under the agreement terms, RFLXF and LSTM will develop a production plan, marketing strategy, and customer database. LSTM will also produce a technical data sheet that aims to qualify potential customers requiring CSPG to test and evaluate the efficacy and compatibility of a new, conductive, additive anode material in a chemistry or format required for their specific application.

“We are thrilled to come on board with Reflex Advanced Materials and provide our go-to-market, commercial and technical expertise,” said Chris Whiteley, CEO of Lone Star Tech Minerals. “We look forward to the partnership and leveraging our extensive industry knowledge and marketing expertise, including downstream battery OEMs and other high tech end users of CSPG where margins are highest, and demand is still diverse and abundant.”

Graphite is critical for manufacturing battery electrodes, motors, and generators, as well as a lubricant in circuit breaker and switch production. EV manufacturers specifically prefer lithium-ion batteries over other technologies because they efficiently store and release lithium ions over multiple charge-discharge cycles, leading to longer driving ranges and shorter charging times.

Historically, the Ruby Graphite Deposit produced roughly 2,400 tons from 1902 to 1948. RFLX now holds mining rights for 755 hectares with 96 federal lode mining claims and will use targets identified using historical data and the 43-101 technical report dated January 31, 2023. The company submitted a permit application in March 2023 and plans to start implementing an initial plan to drill 3,500 meters at an average core depth of 130 meters this summer.

Chinese producers provide most of the graphite sold in North America today, raising concerns in Washington that the U.S. is overdependent on foreign sources (https://ibn.fm/jsjp5). To combat the problem, the U.S. Department of Energy plans to award $2.8 billion to expand domestic EV battery manufacturing, including graphite processing (https://ibn.fm/0Y42C). Reflex Advanced Materials are aiming to take advantage of these shifting economic conditions by expanding the Ruby Graphite Deposit in advance of increased demand.

For more information, visit the company’s website at www.ReflexMaterials.com.

NOTE TO INVESTORS: The latest news and updates relating to RFLXF are available in the company’s newsroom at https://ibn.fm/RFLXF

• Digital money is replacing physical cash, and FEXD is developing mobile transaction platforms and services that are helping implement the coming changes in the fintech market
• FEXD plans to acquire and merge with companies that include country-based fintech pioneers with global scalability, fintech service providers, companies with large customer bases, and more
• The company is helping ensure humanity has a path forward from archaic and restrictive cash systems – reducing poverty, improving the lives of the unbanked, providing critical financial options for migrant workers, connecting families and communities, empowering charities and women, and educating underprivileged children

With plans to offer a diverse portfolio of fintech-related products and services for consumers and businesses in the United States, South Asia, East Asia, Africa, Europe, and Latin America, Fintech Ecosystem Development (NASDAQ: FEXD) continues to move forward in the service of underserved and overlooked markets within the global financial ecosystem. The FEXD management team has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector, driving the move to a cashless society.

Digital money is replacing physical cash, with consumers able to buy products and services anywhere in the world and make payments across borders. FEXD is developing mobile transaction platforms and services that are helping implement the coming changes – especially in underserved and overlooked markets like rural areas and Asia, the Middle East, Africa, and Latin America.

FEXD supports the United Nations’ Sustainable Development Goal to reduce cross-border transaction costs from 7 percent to 3 percent. The company’s use of advanced technology is lowering fintech costs and international fees for cross-border transactions.

The company’s growth strategy includes seeking the acquisition and merging of high growth fintech primarily operating in South Asia. The target companies that FEXD plans to acquire and merge with will help the company grow to $1 billion and more in annual revenues as a part of the global fintech ecosystem it is developing. The companies that FEXD plans to acquire/merge with will exhibit the following characteristics:

• Country-based fintech pioneers with the global scalability
• Fintech service providers that will benefit from integrating more advanced technologies
• Fintech companies with a large existing customer base
• A shared interest in making an impact by bringing mobile transaction services to under-served markets
• Growth-oriented management teams
• Attractive valuation

FEXD is committed to supporting the fintech and digital money processes in developing countries and cultures. Using its keen understanding of market needs in regions worldwide, the company is helping ensure humanity has a path forward from an unhygienic cash system – reducing poverty, improving the lives of the unbanked, offering securing and savings options for migrant workers, connecting families and communities, empowering charities and women, and educating underprivileged children.

According to McKinsey research, there are four major trends driving the growth of digital payments worldwide, especially in emerging markets like Africa and Southeast Asia, where low banking penetration allows payment providers to capture untapped potential and reach underserved populations. The first trend, the pandemic, accelerated the contactless digital payments frontier. Second, e-commerce continues to grow and evolve, with global volumes expected to increase by 12 to 15 percent annually by 2025. Third, the government is pushing for cashless payments to facilitate interoperability, plug tax leakages, and ensure effective aid distribution. Lastly, McKinsey points out investor appetites for digital payments, leading to a proliferation of payments-focused fintechs (https://ibn.fm/oOGOX).

Many areas of the world have severely underserved financial service markets. Millions of people require faster and cheaper ways to transfer money directly across borders to fund business transactions and provide support. Mobile money platforms provide a solution to the billions of people who own a cell phone but do not have access to a bank. FEXD services allow people in other countries to access USD online accounts that are FDIC insured.

For more information, visit the company’s website at www.FintechEcoSys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

• Lexaria recently completed its animal study HOR-A22-1 showing its patented DehydraTECH(TM) technology dramatically enhanced the oral delivery of estradiol, a type of estrogen hormone
• The use of DehydraTECH resulted in ~900% higher peak concentration of estradiol in the bloodstream compared to the control, as well as a 2,000% increase in the levels of estrone
• Estrone is a type of estrogen that can be reversibly made from estradiol in certain tissues within the female body
• The study HOR-A22-1 also revealed that DehydraTECH resulted in 1,500% and 12,500% higher exposure to estradiol and estrone over time, respectively, compared to the control
• Lexaria also announced the closing of a public offering that raised approximately $2 million in gross proceeds

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported that it had completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol (https://ibn.fm/ywP2y).

Performed in 20 female Sprague-Dawley rats, the pharmacokinetic study compared a DehydraTECH-estradiol formulation to a generic estradiol composition, both containing 10 mg/kg of estradiol, to evaluate the ability of DehydraTECH to enhance the delivery properties of the orally administered hormone. Once dosing was completed, blood was collected up to 48 hours post-dosing, with the concentration of estradiol and estrone determined thereafter.

Estradiol is a major female sex hormone and the most common form of estrogen in women of childbearing age. It is normally made in the ovaries (although it is also manufactured in the testicles in men, albeit in small quantities) but can be administered as an oral tablet, topical gel or patch, cream, or injection to reduce the symptoms of menopause and protect bone health. It is also found in birth control products. Put simply, estradiol is an important element of therapeutic products in the women’s health sector. On the other hand, Estrone is the only type of estrogen that females continue to manufacture after menopause. It is primarily made in the adrenal glands (in both males and females), although it is also reversibly manufactured from estradiol in tissues found in the mammary gland, uterus, and liver, a factor that informed the study’s measurement of estrone levels.

The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (“Cmax”) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL compared to the control’s 0.302 ng/mL.

Additionally, the study evaluated the area under the curve (“AUC”), a parameter that gave insight into the total delivery of estradiol over time as well as the extent of exposure to estrone. The AUC was 3.9 hr.ng/mL for estradiol and 32.6 hr.ng/mL for estrone when the DehydraTECH-processed composition was used. In comparison, the AUC after administering the control was non-detectable for both estradiol and estrone, as it was below 0.25 ng/mL, the lower limit of quantitation of the assay. This means the AUC findings were 1,500% and 12,500% greater than the control for estradiol and estrone, respectively.

Considered an additional step that is readily incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical products, DehydraTECH has been shown to improve the proportion of the drug delivered into the bloodstream (bioavailability) and the absorption of drugs into the brain tissue. Among the drugs that can benefit from these improvements is oral estradiol, which has minimal bioavailability (2% to 10%) due to gut and liver metabolism (https://ibn.fm/kbdx1). This, according to Lexaria, often necessitates high dosages to achieve the desired beneficial effect; but this can, in turn, lead to unwanted side effects. Thus, incorporating DehydraTECH into the manufacturing process of oral estradiol and potentially other human hormone therapies may enhance their oral delivery.

The animal study HOR-A22-1, which is part of Lexaria’s efforts to pursue multiple paths to success by investigating several large market opportunities, represents a foray into the hormone replacement market estimated to grow from $31.06 billion in 2019 to an estimated $46.50 billion by 2027, a 5.1% CAGR (https://ibn.fm/PnAIK).

Meanwhile, Lexaria also announced the closing of its public offering of 2,106,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock. The offering generated approximately $2.0 million in gross proceeds.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Smart organizations are encouraged to meet certain standards and regulations to protect data against cybersecurity threats
• With more than 15 billion user credentials scattered across the dark web, the threat is real
• CEO notes that compliance is an important driver for security, and organizations should never view it as a mere technical nuisance

Complying with security requirements should be about more than just ticking off mandatory checkboxes, says CISO Global (NASDAQ: CISO) CEO David Jemmett (https://ibn.fm/dDN38). CISO Global, formerly Cerberus Cyber Sentinel Corp., works closely with companies to provide essential protection, and Jemmett is a recognized expert in the field of cybersecurity.

“Today, all organizations are required or encouraged to meet certain standards and regulations to protect their data against cybersecurity threats,” writes Jemmett in a guest essay for The Last Watchdog. “The regulations vary across countries and industries, but they are designed to protect customers from the threat of posed data breaches.”

That threat is real, notes Jemmett, citing estimates that currently more than 15 billion user credentials are scattered across the dark web. “The importance of compliance is clear to see,” he writes. “In spite of this, many organizations today still see compliance as a nuisance, rather than a business enabler. All too often, organizations will analyze compliance requirements and harden their systems and practices to meet them, without really thinking about their importance to the business. Instead, they will tick the mandatory checkboxes, even if security measures haven’t been enacted, and file the record away as quickly as possible.”

This approach is dangerous, explains Jemmett, noting that single “point-in-time” compliance doesn’t cut it in today’s threat landscape. “Compliance is no longer a ‘set and forget’ security framework,” he continues. “To keep up to speed in today’s evolving threat landscape, compliance is a process that must be maintained continuously.”

In his essay, Jemmett offers several tips to help companies implement an effective cybersecurity compliance strategy, providing timely, relevant protection against current as well as new and emerging threats. These suggestions include staying up-to-date with the evolving and growing attack surface, taking a risk-based approach and remembering that cybersecurity is a culture, not a product. “Compliance is an important driver for security, and organizations should never view it as a mere technical nuisance. Cybersecurity is a critical business enabler today, and those that get it right will excel. Those that get it wrong, and do not prioritize their defenses, could stand to lose everything,” Jemmett concluded.

CISO Global is gaining recognition as a leading provider of global cybersecurity and compliance as it rapidly expands by acquiring world-class cybersecurity, secured-managed services and compliance companies. These acquisitions bring top-tier talent to the CISO table, enabling the company to utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations, mitigating continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment
• BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services
• The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which drew over 6,000 attendees from a wide variety of international life sciences disciplines
• BiondVax’s NanoAb drug candidate pipeline has expanded focus on immune system cytokine targets for treating psoriasis and psoriatic arthritis

Israel-based biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV) is building on positive preclinical data regarding its innovative inhaled anti-SARS-CoV-2 nanosized antibody (NanoAb) product with plans to develop further NanoAbs targeting immune system cytokines while the company expands its frontiers by beginning to offer contract development and manufacturing organization (“CDMO”) services.

BiondVax showcased its CDMO services and expertise at the premier conference for international Life Science and HealthTech industries earlier this month in Israel. The 21st annual Biomed Israel drew more than 6,000 industry leaders, scientists, engineers, physicians, and investors from over 45 countries, providing BiondVax a worldwide stage for exhibiting its potential blockbuster products and state-of-the-art assets and services.

“Senior executives and delegations from multinationals, big pharma, medical devices, tech giants and international investors in the health industry come to Israel each May to ‘shop for’ innovation in the field, in search of creative solutions, products and technologies, and the next big thing,” Biomed Israel Co-chairwoman Ruti Alon stated in a news release about the event (https://ibn.fm/jWiGl).

BiondVax has gained significant expertise in developing and producing current good manufacturing practice (“cGMP”) compliant drug candidates, working from preclinical stage to Phase 3 clinical trials. Making its cGMP manufacturing facility available for the development of other companies’ products helps to advance the potential of improving medical therapies and responding to unmet medical needs.

The company’s CDMO services include aseptic filling, upstream and downstream process development, as well as analytical model development. BiondVax is contracting its suite of boutique end-to-end services (https://ibn.fm/ArbDX) to large pharmaceutical and biotech companies, alternative protein food tech companies, and smaller development-stage companies in general.

Offering CDMO services “allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” CEO Amir Reichman stated in a year-end letter to shareholders (https://ibn.fm/FRmQg).

“The team already knows how to work together. The team has experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — everything works; it’s an oiled machine. Also the capacity and the capabilities are there,” Reichman said in a March interview with Digital Niche Agency that addressed BiondVax’s efforts to strengthen its value for its shareholders (https://ibn.fm/IAcxF).

A recent statement on the company’s quarterly financial results noted that the company has begun R&D activities for the innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis, both large market disorders with large unmet medical needs.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• MULN received an order for one thousand class 3 trucks from its dealer partner, Randy Marion Automotive
• The company is excited about entering the next phase of its commercial launch with the Mullen THREE
• Mullen inked a $15 million vehicle purchase agreement with the MGT Lease Company for 250 class 3 cab chassis EV trucks

On the heels of several purchase agreements and orders, Mullen Automotive (NASDAQ: MULN) is experiencing impressive momentum as it continues to focus on growing in the electric vehicle space. Most recently, the company received a 1,000-unit purchase order (https://ibn.fm/2tLyU) and announced a $15.7 million vehicle purchase order with a lease company, both for its Mullen THREE class 3 truck (https://ibn.fm/y31v4).

The order for one thousand class 3 trucks came from Mullen’s dealer partner, Randy Marion Automotive, which earlier this month received the first class 3 demonstration vehicle for customer test drives and demonstrations. “Based on the tremendous interest we received on the Mullen class 3 truck, we placed our 1,000-vehicle order,” said Brad Sigmon, the fleet general manager and vice president of Randy Marion Automotive fleet operations. “We have a lineup of our customers waiting to pilot this truck including Duke Energy, Lowes and UNC-Charlotte.”

Mullen has announced that the class 3 truck will be priced at $68,500 and includes an estimated 130-mile range along with a 5,800-pound payload and capability of carrying a 14-foot box with more than 1,000 cubic feet of cargo capacity.

Mullen chief commercial officer John Schwegman noted that the company is excited about entering the next phase of its commercial launch with the Mullen THREE, which he identified as “the customers, piloting, testing and evaluation stage. Demand has been strong since we introduced this product and the aggressive price point. We are excited to get customers behind the wheel of our class 3 product.”

In addition, Mullen signed a vehicle purchase agreement, valued at more than $15.7 million, with MGT Lease Company, for 250 class 3 cab chassis EV trucks. According to the agreement, Mullen will begin delivering the first of the trucks in August 2023, with all vehicles being delivered by the end of the year.

A growing commercial vehicle sales and leasing company based in North Carolina, MGT is focused on a customer base that is looking for last-mile delivery solutions, such as package delivery and retail, along with vocations such as plumbing and electrical. MGT has ordered the all-electric class 3 EV cab chassis trucks for addition to its short- and long-term fleet leasing portfolio. MGT has worked with Mullen before; the company initially purchased EV cargo vans earlier this year. “We are very happy with the Mullen EV cargo van and have received great customer feedback and are now looking forward to expanding into Mullen’s commercial class 3 truck,” said Greg Striker, a partner at MGT Lease Co.

Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.

For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Gene Therapy’s Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga.

Click Here for the full article

The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex’s innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer.

The featured video highlights the compelling story of Jacqueline Marino, a participant in the Phase 1 segment of Genprex’s Phase 1/2 Acclaim-1 clinical trial. Marino, diagnosed with non-small cell lung cancer (“NSCLC”), offers an inspiring account of her experience with REQORSA(R) Immunogene Therapy, Genprex’s flagship drug candidate, in combination with Tagrisso(R).

Marino’s narrative centers on the significant positive impact REQORSA has had on her life. Her treating physician observed that her lung cancer lesions remained stable, devoid of any signs of growth. This stability, combined with an extended period of Progression-Free Survival (“PFS”), has led to an enhanced quality of life and invaluable additional time for Marino.

REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC. The Acclaim-1 trial evaluates the safety and efficacy of combining REQORSA with Tagrisso in patients with advanced EGFR mutant NSCLC who have experienced disease progression after previous treatments.

During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One patient previously treated with standard of care therapies such as osimertinib had a partial remission (“PR”) by investigator evaluation and treatment is ongoing after 16 cycles, which is approximately 10.5 months. Another patient previously treated with osimertinib, has stable disease and treatment is ongoing after 14 cycles, or approximately 9 months. The extended and ongoing progression free survival (“PFS”) of each of these patients is significantly greater than the median PFS observed from treatment with osimertinib alone in this treatment setting in several prior clinical trials and is consistent with long-term PFS seen in prior clinical trials of REQORSA. These findings underscore the potential of REQORSA in reshaping the landscape of non-small cell lung cancer.

The release of the patient video interview on Benzinga coincides with the successful completion of the Phase 1 portion of the Acclaim-1 clinical trial. The compelling patient story, combined with the Safety Review Committee’s approval to proceed with the Phase 2 expansion segment, signify significant milestones in the development of REQORSA Immunogene Therapy.

While REQORSA is currently in early-stage clinical studies and will require successful large scale studies prior to regulatory approval and commercial availability, the patient video interview on Benzinga provides a captivating glimpse into the transformative potential of gene therapy. Marino’s journey serves as an inspirational testament to the promise of REQORSA in addressing the critical needs of NSCLC patients.

To watch Jacqueline Marino’s powerful story and delve deeper into REQORSA Immunogene Therapy, visit the featured video on Benzinga.

*It is important to note that REQORSA is an investigational drug and has not received approval from the U.S. Food and Drug Administration or any other regulatory authority. The experiences shared in the video are unique to Jacqueline Marino and may not be representative of the outcomes experienced by other patients undergoing REQORSA treatment.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX